Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Retrieved on:
Monday, September 27, 2021
Idiopathic pulmonary fibrosis, HSCT, Event, Private Securities Litigation Reform Act, Weakness, Pain scale, Program, Safety, SNDX, Entinostat, Macrophage, Food, News, JAK, Investor, UCB, Webcast, LinkedIn, Form, Twitter, Monocyte, Survival, Association, Partnership, Annual report, Orphan, Patient, Risk, Fatigue, Solution, Goldman Sachs, U.S. Securities and Exchange Commission, FDA, Exertion, Marketing, Company, Tissue, Forward-looking statement, Fibrosis, Time, Society, Form 10-K, Diagnosis, Security (finance), U.S.-Japan Caucus, GVHD, HDAC, IPF, Scar, COVID-19, Research, Chronic cough, Nasdaq, Skin, Pharmaceutical industry, Fine chemical
"Incyte is a proven leader in the development and commercialization of many important innovative therapies, including a treatment for GVHD.
Key Points:
- "Incyte is a proven leader in the development and commercialization of many important innovative therapies, including a treatment for GVHD.
- Syndax and Incyte are seeking to develop axatilimab as a backbone therapy for patients with cGVHD as well as in additional immune-mediated diseases where CSF-1R-dependent monocytes and macrophages are believed to contribute to organ fibrosis.
- Enrollment continues in the ongoing global pivotal Phase 2 AGAVE-201 trial of axatilimab monotherapy in patients with cGVHD, with topline data expected in 2023.
- Under the terms of the agreement, Incyte will lead global commercial activities for axatilimab across all indications.